Skip to content

tDCS for Laryngeal Dystonia

Network Targeted Transcranial Direct Current Stimulation (tDCS) as a Treatment for Laryngeal Dystonia (LD)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06830174
Enrollment
10
Registered
2025-02-17
Start date
2025-04-14
Completion date
2026-12-01
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal Dystonia

Brief summary

This project will apply transcranial direct current stimulation (tDCS) to multiple brain areas to evaluate the effects as a potential treatment for laryngeal dystonia (formerly spasmodic dysphonia).

Detailed description

Baseline neuroimaging data will be acquired from all participants via MRI, EEG. Each participant will be seen for multiple testing sessions over a five day period. LD participants will undergo the neuromodulation (HD-tDCS Stimulation) for twenty minutes while engaged in watching videos/movies or performing a word production task.

Interventions

DEVICEStarstim system

Transcranial direct current stimulation (tDCS)

Sponsors

Yale University
Lead SponsorOTHER
National Spasmodic Dysphonia Association
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

Subjects and staff will be blind during the study and that subjects will be told of their assignment at the follow-up visit.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Participants must be clinically evaluated for the diagnosis of LD or have the proof of LD diagnosis. (Not applicable for control participants) * No other known or history of speech, voice disorder other than LD. * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study * Must not be pregnant.

Exclusion criteria

* All individuals who do not meet the above mentioned criteria are excluded from the study. * Subjects with a history of epilepsy or depression or is claustrophobic.

Design outcomes

Primary

MeasureTime frameDescription
Change in Cepstral peak prominence (CPP)daily on Day 1-Day 5Cepstral peak prominence (CPP) as a robust objective measure of voice quality in the active, sham and no stimulation conditions.
Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)daily on Day 1-Day 5Its primary purpose is to describe the severity of auditory-perceptual attributes of a voice problem, in a way that can be communicated among clinicians

Countries

United States

Contacts

CONTACTNabin Koirala, PhD
nabin.koirala@yale.edu203 7852527
PRINCIPAL_INVESTIGATORNabin Koirala, PhD

Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026